Atgam

(anti-thymocyte globulin)

Phase 3Small molecule

This medication suppresses the immune system to prevent it from attacking a transplanted kidney or to treat aplastic anemia, a condition where the body fails to produce enough new blood cells.[1] Atgam is currently being investigated across 41 indications[3], with its most advanced program in Phase 3.[1]

Atgam is one of 850 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

Indications

189

Total Trials

Active Trials

849

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Aplastic AnemiaRecruiting

Liver TransplantActive, not recruiting

Kidney CancerActive, not recruiting

IschemiaActive, not recruiting

T-Cell Non-Hodgkin LymphomaActive, not recruiting

Anaplastic Large Cell LymphomaActive, not recruiting

Tic DisorderActive, not recruiting

LymphomaActive, not recruiting

Severe Combined ImmunodeficiencyActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Aplastic AnemiaPhase 2

Recruiting

Liver TransplantPhase 1

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

IschemiaPreclinical

Active, not recruiting

T-Cell Non-Hodgkin LymphomaPhase 1/Phase 2

Active, not recruiting

Anaplastic Large Cell LymphomaPreclinical

Active, not recruiting

Tic DisorderPreclinical

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Severe Combined ImmunodeficiencyPhase 1/Phase 2

Active, not recruiting

Showing 10 of 41 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Atgam

Novartis

Phase 3

3 2

Tecentriq

Roche

Preclinical

36 3

Tykerb

GSK

Preclinical

80 4

Adriamycin

GGynecologic Oncology Group

Preclinical

87 5

Avastin

BBio-Thera Solutions

Preclinical

153 6

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 7

Prolia

Amgen

Preclinical

14 8

Gemzar

GGynecologic Oncology Group

Preclinical

22 9

Lexiscan

Astellas

Preclinical

1 10

Adenocard

Astellas

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Systemic Sclerosis

NCT03630211

Q2 2027

Phase 2Recruiting

Cell Therapy

NCT02727803

Phase 2Active, not recruiting

Transplantation

NCT04395222

Phase 1Recruiting

Severe Aplastic Anemia

NCT05757310

Q3 2027

Phase 2Not yet recruiting

Neuroblastoma

NCT05303727

Phase 1/2Recruiting

Stem Cell Transplantation

NCT04224558

Clinical

Trials by Indication[1]

Stem Cell Transplant17 trials

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Terminated·UUniversity of California, San Francisco·N/A·NCT00301860·8 enrolled

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00880815·60 enrolled

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Completed·UUniversity of Nebraska·Phase 2·NCT00611351·5 enrolled

Show 14 more trials

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00448201·71 enrolled

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

Completed·—·Phase 1·NCT00376480·19 enrolled

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

Completed·—·Phase 2·NCT00627666·52 enrolled

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00281879·200 enrolled

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00919503·98 enrolled

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01056614·23 enrolled

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00346359·40 enrolled

Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00392782·24 enrolled

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Completed·NNorthside Hospital, Inc.·Phase 2·NCT00787761·24 enrolled

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

Completed·UUniversity of California, San Francisco·N/A·NCT00296023·25 enrolled

Allogeneic Stem Cell Transplant for CLL

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01629511·15 enrolled

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

Unknown status·IInstitut Paoli-Calmettes·Phase 2·NCT00740467·50 enrolled

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00617929·12 enrolled

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00053196·82 enrolled

Bone Marrow Transplantation11 trials

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00303719·342 enrolled

Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00002534

Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders

Completed·—·N/A·NCT00005893

Show 8 more trials

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 4·NCT00003398·45 enrolled

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005641

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005852

Bone Marrow Transplantation in Treating Patients With Leukemia

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 3·NCT00006451

Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia

Completed·RRoswell Park Cancer Institute·Phase 3·NCT00004474·224 enrolled

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

Completed·UUnknown Sponsor·Phase 2/3·NCT00004255

Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004323·10 enrolled

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

Terminated·—·N/A·NCT00006054

Severe Aplastic Anemia8 trials

Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia

Unknown status·—·Phase 2·NCT01759732·10 enrolled

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Completed·—·Phase 1·NCT00054236·55 enrolled

Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia

Completed·TThe Cleveland Clinic·Phase 2·NCT01231841·20 enrolled

Show 5 more trials

Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00260689·136 enrolled

Haploidentical HCT for Severe Aplastic Anemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT04558736·21 enrolled

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00343785·21 enrolled

A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

Recruiting·—·Phase 1·NCT05757310·6 enrolled

Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT00354419·30 enrolled

Hematologic Cancer8 trials

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003661·3 enrolled

Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer

Withdrawn·—·Phase 1·NCT00003435

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer

Terminated·NNorthside Hospital, Inc.·Phase 2·NCT00827099·5 enrolled

Show 5 more trials

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT00290628·43 enrolled

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT00304018·5 enrolled

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003270·20 enrolled

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

Completed·—·Phase 2·NCT00003335·44 enrolled

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT00301951·7 enrolled

Transplantation7 trials

Allogeneic Transplantation From Related Haploidentical Donors

Completed·SStanford University·Phase 2·NCT00185692·16 enrolled

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

Completed·WWake Forest University Health Sciences·Phase 4·NCT00331162·222 enrolled

Advancing Transplantation Outcomes in Children

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06055608·200 enrolled

Show 4 more trials

Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation

Unknown status·MMcMaster University·Phase 3·NCT01217723·198 enrolled

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT01810588·270 enrolled

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT04395222·21 enrolled

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00038831·47 enrolled

74 more indications

Multiple Myeloma7 trials

Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

Completed·UUniversity of Rochester·Phase 1·NCT00317798·18 enrolled

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma

Terminated·MMayo Clinic·Phase 2·NCT00635024·1 enrolled

Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment

Completed·IInstitut Paoli-Calmettes·Phase 2·NCT00802568·48 enrolled

Show 4 more trials

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Terminated·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT01534143·1 enrolled

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT01758328·29 enrolled

Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00378768·12 enrolled

Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma

Withdrawn·MMayo Clinic·Phase 1/2·NCT00995059

Hematologic Malignancies7 trials

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·—·Phase 2·NCT01093586·14 enrolled

Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Completed·SSumithira Vasu·Phase 1·NCT02122081·33 enrolled

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

Completed·SStanford University·Phase 2·NCT00185640·303 enrolled

Show 4 more trials

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Terminated·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01118013·6 enrolled

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03622788·16 enrolled

Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·—·Phase 1·NCT02129582·14 enrolled

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Completed·—·Phase 2·NCT00006379·58 enrolled

Lymphoma6 trials

Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT00882895·18 enrolled

Autologous and Allogeneic Transplant for Relapsed Lymphoma

Completed·—·Phase 1/2·NCT00802113·30 enrolled

Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma

Withdrawn·AAIDS Malignancy Consortium·Phase 2·NCT00024128

Show 3 more trials

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Completed·SStanford University·Phase 2·NCT00896493·38 enrolled

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07257419·60 enrolled

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Unknown status·JJoseph Tuscano·Phase 2·NCT01811368·20 enrolled

Myelodysplastic Syndrome6 trials

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01168219·68 enrolled

Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome

Completed· Sanofi logo

Sanofi·Phase 2·NCT00017550

Biological Therapy in Treating Patients With Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00005853

Show 3 more trials

HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors

Unknown status·—·Phase 1/2·NCT01509300·10 enrolled

S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome

Completed·SSWOG Cancer Research Network·Phase 2·NCT00016419·130 enrolled

T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002718·31 enrolled

Stem Cell Transplantation5 trials

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·NNorthwestern University·Phase 1·NCT00004904

Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00004145·16 enrolled

Stem Cell Transplantation in Crohn's Disease

Recruiting·—·Phase 1/2·NCT04224558·15 enrolled

Show 2 more trials

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003396·42 enrolled

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

Unknown status·MMilton S. Hershey Medical Center·Phase 2·NCT00084695·25 enrolled

Aplastic Anemia5 trials

Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia

Unknown status·—·N/A·NCT00017654·3 enrolled

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Unknown status·UUniversity of California, San Francisco·N/A·NCT00295997·35 enrolled

Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia

Completed·—·Phase 1/2·NCT01105273·12 enrolled

Show 2 more trials

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2/3·NCT00003816·361 enrolled

Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01624805·140 enrolled

Acute Myeloid Leukemia4 trials

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00553202·158 enrolled

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Withdrawn·EEastern Cooperative Oncology Group·Phase 2·NCT00101140

Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Completed·—·Phase 2·NCT01020734·263 enrolled

Show 1 more trial

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00070135·121 enrolled

Leukemia4 trials

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00055653

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03096782·6 enrolled

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Completed·RRobert Lowsky·Phase 2·NCT02424968·18 enrolled

Show 1 more trial

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

Completed·—·Phase 1·NCT01020539·18 enrolled

Kidney Transplant4 trials

Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01790594·46 enrolled

The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients

Completed·MMayo Clinic·Phase 4·NCT00275535·165 enrolled

Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00346151·5 enrolled

Show 1 more trial

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

Unknown status·TTolera Therapeutics, Inc·Phase 1/2·NCT01154387·85 enrolled

Hematopoietic Cell Transplantation3 trials

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

Completed·SStanford University·Phase 2·NCT03734601·22 enrolled

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

Completed·UUniversity of Utah·Phase 2·NCT00795132·47 enrolled

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Terminated·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT01116232·4 enrolled

Type 1 Diabetes3 trials

ATG-GCSF in New Onset Type 1 Diabetes

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT02215200·89 enrolled

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Recruiting·—·Phase 1/2·NCT07061574·120 enrolled

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

Terminated·UUniversity of Minnesota·Phase 1/2·NCT00672204·23 enrolled

Fanconi Anemia3 trials

A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03600909·3 enrolled

Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00630253·31 enrolled

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00258427·14 enrolled

Breast Cancer3 trials

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

Terminated·UUniversity of California, San Diego·Phase 2·NCT00074269·5 enrolled

Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00365287·148 enrolled

Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer

Terminated·EEuropean Institute of Oncology·Phase 2·NCT01375023·3 enrolled

Peripheral Blood Stem Cell Transplantation2 trials

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT03602898

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03615144·1 enrolled

Bone Marrow Failure Syndrome2 trials

Stem Cell Transplant for Bone Marrow Failure Syndromes

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00176878·10 enrolled

Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease

Completed·UUniversity of California, San Francisco·Phase 1·NCT00295971·21 enrolled

Anemia2 trials

Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00489281·43 enrolled

Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia

Completed·UUniversity of Minnesota·Phase 1/2·NCT00005898·30 enrolled

Prophylaxis2 trials

Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02876679·94 enrolled

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

Active, not recruiting·MMcMaster University·Phase 2·NCT04202835·80 enrolled

Lymphoid Malignancies2 trials

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01664910·27 enrolled

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00439556·40 enrolled

Graft Versus Host Disease2 trials

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Terminated·VVanderbilt-Ingram Cancer Center·N/A·NCT00608517·6 enrolled

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Completed·—·Phase 2·NCT00589563·32 enrolled

Acute Leukemia2 trials

Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02083250·70 enrolled

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Unknown status·DDutch Childhood Oncology Group·N/A·NCT00550992·445 enrolled

Conditioning2 trials

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Terminated·SStanford University·Phase 3·NCT00568633·58 enrolled

Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired SAA Receiving sUCBT

Unknown status·—··NCT06039436·72 enrolled

Liver Transplant2 trials

A Study of Thymoglobulin and Tacrolimus in Liver Transplant

Unknown status·UUniversity of Nebraska·Phase 4·NCT00564538·100 enrolled

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02188719·15 enrolled

Tic Disorder2 trials

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00176865·19 enrolled

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Unknown status·—·N/A·NCT00006056·40 enrolled

Phase 22 trials

Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01856257·71 enrolled

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Terminated·SStanford University·Phase 2·NCT00482053·3 enrolled

Hematological Malignancies2 trials

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00566696·73 enrolled

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT05579769·3 enrolled

Infusion2 trials

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Terminated·EEverett Meyer·Phase 1/2·NCT01050764·10 enrolled

Infusion of Expanded Cord Blood T Cells

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT00972101

Autoimmune Disease2 trials

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Active, not recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT00716066·53 enrolled

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

Unknown status·—·N/A·NCT00006055·10 enrolled

Bone Marrow Transplant2 trials

Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer

Completed·TTemple University·Phase 2·NCT00002809·10 enrolled

Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00028730·25 enrolled

Chronic Lymphocytic Leukemia2 trials

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00425802·61 enrolled

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Completed·GGerman CLL Study Group·Phase 1/2·NCT00281983·100 enrolled

Systemic Sclerosis2 trials

Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00016458·20 enrolled

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Recruiting·PPaul Szabolcs·Phase 2·NCT03630211·8 enrolled

Multiple Sclerosis1 trial

Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00014755·35 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00053989·41 enrolled

Metabolic Disease1 trial

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003662·90 enrolled

Chronic Myelogenous Leukemia1 trial

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT00305708·40 enrolled

Advanced1 trial

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00719849·13 enrolled

Donor1 trial

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Terminated·MMemorial Sloan Kettering Cancer Center·N/A·NCT01598025·3 enrolled

Tolerance1 trial

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02029638·4 enrolled

Malignant Solid Tumors1 trial

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00436761·20 enrolled

Pilot Study1 trial

Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

Completed·—·Phase 2·NCT00003336·6 enrolled

Recurrent or Metastatic1 trial

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Completed·—·N/A·NCT00521430·30 enrolled

Dyskeratosis Congenita1 trial

Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT02162420·61 enrolled

APL1 trial

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01390402·6 enrolled

Myelodysplastic Syndromes1 trial

Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00217386·30 enrolled

HSCT1 trial

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT01033552·32 enrolled

ART1 trial

Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment

Completed·SSwedish Medical Center·N/A·NCT00714480·3 enrolled

Scleroderma1 trial

Scleroderma Treatment With Autologous Transplant (STAT) Study

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01413100·21 enrolled

Memory1 trial

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT02790515·170 enrolled

Severe Combined Immunodeficiency1 trial

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT03597594·4 enrolled

Treatment1 trial

Diabetes Islet Preservation Immune Treatment

Withdrawn·CCamillo Ricordi and Jay Skyler·Phase 1/2·NCT02586831

Completed·UUniversity of Alberta·Phase 1/2·NCT02821026·4 enrolled

Islet Transplantation1 trial

Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation

Completed·UUniversity of Minnesota·Phase 1/2·NCT00286624·6 enrolled

Hematologic Disease1 trial

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003913·390 enrolled

Anaplastic Large Cell Lymphoma1 trial

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Unknown status·EEuropean Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma·N/A·NCT00317408·96 enrolled

Juvenile Myelomonocytic Leukemia1 trial

Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00025038·100 enrolled

Metastatic Melanoma1 trial

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

Terminated·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT00003552

Histiocytosis1 trial

Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00334672·288 enrolled

Cell Therapy1 trial

Personalized NK Cell Therapy in CBT

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02727803·100 enrolled

Non-myeloablative Conditioning1 trial

Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00305682·295 enrolled

Neuroblastoma1 trial

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05303727·64 enrolled

Myeloproliferative Disorder1 trial

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00054340

Bone Marrow Failure Disorders1 trial

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Completed·RRoswell Park Cancer Institute·N/A·NCT00856388·62 enrolled

T-cell non-Hodgkin lymphoma1 trial

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01701986·64 enrolled

Kidney Cancer1 trial

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Completed·UUniversity of Rochester·Phase 2·NCT00262886·35 enrolled

Outcome1 trial

Outcomes of Patients After Allo-HSCT With Decitabine and NAC

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT04945096·100 enrolled

Genetic Disorder1 trial

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008307·52 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents

Unknown status·—·Phase 1/2·NCT02014506·30 enrolled

Refractory Solid Tumors1 trial

Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors

Completed·MMilton S. Hershey Medical Center·Phase 1·NCT00112645·10 enrolled

Allogeneic Stem Cell Transplantation1 trial

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Completed·—·N/A·NCT00068523·10 enrolled

Systemic Lupus Erythematosus1 trial

Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus

Unknown status·—·Phase 1·NCT00017641·10 enrolled

Acute Graft Versus Host Disease1 trial

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Terminated·UUniversity of Nebraska·Phase 2·NCT01044745·20 enrolled

Heart Transplant1 trial

SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance

Completed· Novartis logo

Novartis·Phase 4·NCT01266148·115 enrolled

Unspecified1 trial

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

Recruiting·UUniversity of Florida·Phase 2·NCT06455319·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 189 trial records for anti-thymocyte globulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-thymocyte globulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-thymocyte globulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Atgam

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Stem Cell Transplant17 trials

Bone Marrow Transplantation11 trials

Severe Aplastic Anemia8 trials

Hematologic Cancer8 trials

Transplantation7 trials

Multiple Myeloma7 trials

Hematologic Malignancies7 trials

Lymphoma6 trials

Myelodysplastic Syndrome6 trials

Stem Cell Transplantation5 trials

Aplastic Anemia5 trials

Acute Myeloid Leukemia4 trials

Leukemia4 trials

Kidney Transplant4 trials

Hematopoietic Cell Transplantation3 trials

Type 1 Diabetes3 trials

Fanconi Anemia3 trials

Breast Cancer3 trials

Peripheral Blood Stem Cell Transplantation2 trials

Bone Marrow Failure Syndrome2 trials

Anemia2 trials

Prophylaxis2 trials

Lymphoid Malignancies2 trials

Graft Versus Host Disease2 trials

Acute Leukemia2 trials

Conditioning2 trials

Liver Transplant2 trials

Tic Disorder2 trials

Phase 22 trials

Hematological Malignancies2 trials

Infusion2 trials

Autoimmune Disease2 trials

Bone Marrow Transplant2 trials

Chronic Lymphocytic Leukemia2 trials

Systemic Sclerosis2 trials

Multiple Sclerosis1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Metabolic Disease1 trial

Chronic Myelogenous Leukemia1 trial

Advanced1 trial

Donor1 trial

Tolerance1 trial

Malignant Solid Tumors1 trial

Pilot Study1 trial

Recurrent or Metastatic1 trial

Dyskeratosis Congenita1 trial

APL1 trial

Myelodysplastic Syndromes1 trial

HSCT1 trial

ART1 trial

Scleroderma1 trial

Memory1 trial

Severe Combined Immunodeficiency1 trial

Treatment1 trial

Acute Lymphoblastic Leukemia1 trial

Ischemia1 trial

SLE1 trial

Islet Transplantation1 trial

Hematologic Disease1 trial

Anaplastic Large Cell Lymphoma1 trial

Juvenile Myelomonocytic Leukemia1 trial

Metastatic Melanoma1 trial

Histiocytosis1 trial

Cell Therapy1 trial

Non-myeloablative Conditioning1 trial

Neuroblastoma1 trial

Myeloproliferative Disorder1 trial

Bone Marrow Failure Disorders1 trial

T-cell non-Hodgkin lymphoma1 trial

Kidney Cancer1 trial

Outcome1 trial

Genetic Disorder1 trial